Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Patients With Type 2 Diabetes

Interventions

DRUG

Finerenone

Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy

Trial Locations (1)

RECRUITING

3M, Diabetes and Endocrine Research Center, Hong Kong

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER